Biocore Co., Ltd. completed the acquisition of Cytogenetic and Human Genome division of Seoul Clinical Laboratories.
October 21, 2015 at 05:00 am
Share
Biocore Co., Ltd. agreed to acquire Cytogenetic and Human Genome division of Seoul Clinical Laboratories for KRW 2.9 billion on August 18, 2015. Biocore Co., Ltd will acquire entire business including assets, liabilities, contracts and employees of Cytogenetic and Human Genome division. The Board of Directors passed a resolution for the transaction on August 18, 2015. A meeting of shareholders will be held on September 30, 2015. As on September 30, 2015, the stockholders of Biocore Co., Ltd. approved the transaction. The transaction is expected to complete on September 1, 2015. As on September 1, 2015, the transaction is expected to close on October 21, 2015. Serim Accounting Corporation and Samdo Accounting Corporation acted as the valuation agencies.
Biocore Co., Ltd. completed the acquisition of Cytogenetic and Human Genome division of Seoul Clinical Laboratories on October 21, 2015.
Invites Biocore Co Ltd, formerly BioCore Co Ltd, is a Korea-based company mainly engaged in the provision of medical examination services. The Company operates its business through two segments. The New Drug Development Business segment is involved in the provision of bioequivalence testing, drug in vivo kinetics research, drug analysis in biological samples, toxicity kinetics testing, microanalysis in pharmaceuticals, comparative dissolution testing, and clinical trial consulting. The Biotechnology Business segment is engaged in the provision of customized genome analysis services and the manufacture and sale of diagnostic kits. The Companyâs products are sold under the brand of Bio-Core.
INVITES BIOCORE CO., LTD. 
